Claims Substantiation

Claims substantiation is the discipline of supporting every claim on a supplement label, website, social-media post, retailer page, influencer brief or sales deck with the evidence and regulatory authorisation that the destination market requires. Frameworks differ materially across jurisdictions. The US FTC applies the 'competent and reliable scientific evidence' standard under section 5 of the FTC Act, reinforced by the 2022 Health Products Compliance Guidance: tests, analyses, research, studies or other evidence based on the expertise of qualified professionals, conducted and evaluated objectively, using procedures generally accepted in the profession. FTC has consistently signalled the expectation of human clinical evidence — frequently two adequate and well-controlled trials — for health-positioned claims, with enforcement actions citing absence of clinical evidence on the as-marketed product, over-extrapolation from in vitro or animal data, and ingredient evidence that does not translate to the formulation as sold.

DSHEA section 403(r)(6) authorises structure/function claims for dietary supplements provided they are truthful, substantiated, accompanied by the mandatory FDA disclaimer, and notified to FDA via Form 3952 within 30 days of first marketing; disease claims are not permitted and convert the product to an unapproved drug. The structure/function vs disease boundary is increasingly enforced across all marketing channels including social media, influencer content and retailer-page bullets. EU Regulation (EC) 1924/2006 operates a positive-list pre-market authorisation regime — Article 13 general function claims must use authorised wording on the EU Register, Article 14 reduction-of-disease-risk claims require individual EFSA assessment and Commission authorisation, and botanical claims remain in regulatory limbo with most 'on hold' pending review.

International overlays include the UK ASA and CAP Code enforcing the retained EU claim framework post-Brexit, Health Canada NHP requiring pre-market claim authorisation on the Product Licence, and Australia TGA permitted-indications lists for listed medicines. Defensible global programmes maintain a per-market claims register with authorised wording and substantiation dossier, dose-form-population matching analysis demonstrating evidence-to-product correspondence, and a marketing-content approval workflow gating every channel against the register. The most common failure is channel drift — careful claim review on the primary label and website while social, influencer, retailer pages and customer service drift into unsubstantiated or disease territory.